- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07589075
Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in Induction of Ovulation (SGLT-2/PCOS)
Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in Induction of Ovulation in Women With Polycystic Ovarian Syndrome
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
The study will be a randomized controlled clinical trial. Once the eligibility from screening visit is determined prior to baseline visit, randomization will be made by computer randomization for women who are admitted to Beni-Suef University Hospital. The Sample size will be 500 divided equally into 4 groups calculated with power=0.8.
Before initiation of the study, the population will be divided randomly into 4 equal groups: group A, B, C and D. The adjuvant therapy of each group will be group (A) Metformin , group (B) Dapagliflozin , Group(C) Combined Dapagliflozin-Metformin and group (D) with no adjuvant therapy (control group). The adjuvant therapy will be taken once daily with a main meal and started one month before initiation of letrozole. All groups will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
Ovulation rate (percentage of ovulatory cycles in the whole follow up period),Pregnancy rate (clinical pregnancy will be considered when an intrauterine gestational sac is seen and presence of a fetal heartbeat),Serum progesterone on day 21,Endometrial thickness at the time of ovulation and Weight, waist/hip ratio, height and body mass index (BMI) will be measured
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Banī Suwayf, Egypten, 62517
- Gynecology and Reproductive department in Beni-Suef University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
Pre-menopausal women aged 20-40 with primary or secondary infertility and PCOS which render them unable to become pregnant. Diagnosis of PCOS will based on European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM) criteria, the diagnosis is made when at least two of the following criteria are met: oilgo and/or anovulation (infrequent or no ovulation), clinical and/or biochemical signs of hyperandrogenism including hirsutism, acne and/or increased testosterone levels or polycystic ovaries on ultrasound (defined as those containing at least 12 follicles measuring 2-9 mm in diameter arranged peripherally around an echo-dense stroma and/or with increased ovarian volume of at least 10 ml).
Exclusion Criteria:
Other causes of hyperandrogenism mimic PCOS such as congenital adrenal hyperplasia, Cushing's syndrome, or androgen secreting tumors are excluded.
Persistent hyperprolactinemia, thyroid dysfunction defined as TSH < 0.2 mIU/ML or >5.5 mIU/mL) or patients with menopausal levels of FSH (> 15 mIU/mL) (A normal level within the last year is adequate for enter the study).
Liver disease is defined as AST or ALT > 2 times normal or total bilirubin >2.5 mg/dL, kidney disease defined as BUN > 30 mg/dL or serum creatinine> 1.4 mg/dL or significant anemia defined as Hemoglobin < 10 mg/dL.
Women with Type I or II diabetes mellitus who are poorly controlled (defined as a HA1c level > 7.0%).
Untreated poorly controlled hypertension is defined as a systolic blood pressure ≥ 160 mm Hg or a diastolic ≥ 100 mm Hg obtained on two measures obtained at least 60 minutes apart.
History of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.
Women who have undergone a bariatric surgery procedure in the recent past (<12 months) and are in a period of acute weight loss or have been advised against pregnancy by their bariatric surgeon.
Presence of any urinary symptom such as frequency, urgency, or bloody micturition.
In case of metabolic acidosis, osteoporosis, endometrial hyperplasia, or endometrial neoplasia.
Women who had gonadotropin induction, ovarian drilling before or women with hypergonadotropic hypogonadism or functional ovarian cysts (> 5cm).
Criteria of IVF/ICSI as poor Response, no Eggs or ectopic pregnancy. Women who receive antidiabetic medications such as insulin, thiazolidinediones, acarbose, or sulfonylureas are likely to confound the effects of study medication or who are currently receiving metformin XR for a diagnosis of Type I or Type II diabetes or for PCOS are also specifically excluded.
Concomitant use of medication that could interfere with the absorption, metabolism, and excretion of drugs involved in the study as the use of Furosemide, cimetidine increase metformin concentration and nifedipine enhances the absorption of metformin.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: "metformin"
will take Metformin 1000mg as adjuvant therapy
|
will take Metformin 1000 mg once daily with a main meal and started one month before initiation of the first cycle of induction.
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
|
|
Eksperimentel: "Dapagliflozin"
will take Dapagliflozin 10mg as adjuvant therapy
|
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
will take Dapagliflozin 10mg once daily with a main meal and started one month before initiation of the first cycle of induction.
|
|
Eksperimentel: "Dapagliflozin-Metformin"
will take combined Dapagliflozin-Metformin 5/1000 as adjuvant therapy
|
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
will take Combined Dapagliflozin-Metformin 5/1000mg once daily with a main meal and started one month before initiation of the first cycle of induction.
|
|
Andet: "control"
will take letrozole 2.5mg the no adjuvant therapy
|
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Ovulation rate
Tidsramme: "through study completion, an average of 1 year".
|
percentage of ovulatory cycles
|
"through study completion, an average of 1 year".
|
|
Pregnancy rate
Tidsramme: "through study completion, an average of 1 year".
|
when an intrauterine gestational sac is seen and presence of a fetal heartbeat)
|
"through study completion, an average of 1 year".
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Serum progesterone
Tidsramme: "through study completion, an average of 1 year".
|
Serum progesterone
|
"through study completion, an average of 1 year".
|
|
Endometrial thickness
Tidsramme: "through study completion, an average of 1 year".
|
Endometrial thickness
|
"through study completion, an average of 1 year".
|
|
Weight
Tidsramme: "through study completion, an average of 1 year".
|
Weight in kilogram
|
"through study completion, an average of 1 year".
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IORG2226240
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Fremkaldelse af ægløsning
-
Tunis UniversityIkke rekrutterer endnuPædiatrisk | Fuld mave | Rapid Sequence Induction (RSI)Tunesien
-
Brno University HospitalMasaryk UniversityAfsluttetHigh Flow Oxygen ved præoxygenering under hurtig sekvensinduktion hos spædbørn og små børn (PRSIHFO)Præoxygenering | Rapid Sequence Induction (RSI)Tjekkiet
-
St George's, University of LondonUkendtLuftvejssygelighed | High Flow Oxygen i Rapid Sequence InductionDet Forenede Kongerige
-
University of MalayaUkendtEndotracheal intubation i Bed up Head Elevation Position i Rapid Sequence InductionMalaysia
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...University of MilanAfsluttet300 studerende ved University of Milan School of MedicineItalien
-
Prisma Health-UpstateNational Institute on Drug Abuse (NIDA); Clemson UniversityAfsluttetStandard for pleje | Standard of Care + CBT4CBT | Standard of Care + CBT4CBT + RCForenede Stater
-
Nimble Science Ltd.University of Calgary; Lallemand Health SolutionsAfsluttet
-
University Health Network, TorontoIkke rekrutterer endnu
-
National Taiwan University HospitalAfsluttetPoint-of-care ultralydTaiwan
-
Imperial College LondonAfsluttetProof Of Concept undersøgelseDet Forenede Kongerige
Kliniske forsøg med Metformin 1000 mg
-
Disphar International B.V.Trukket tilbageSammenlignende biotilgængelighedJordan
-
SandozAfsluttet
-
GlaxoSmithKlineAfsluttetDiabetes mellitus, type 2Forenede Stater, Taiwan, Argentina, Canada, Filippinerne, Korea, Republikken, Mexico, Brasilien, Pakistan
-
Chong Kun Dang PharmaceuticalAfsluttetDiabetes mellitus, type IIKorea, Republikken
-
Dong-A ST Co., Ltd.AfsluttetType 2 diabetes mellitusKorea, Republikken
-
SanofiAfsluttet
-
LG ChemUkendt
-
LG ChemAfsluttet
-
LG ChemAfsluttet